Is the new sleep apnea pill the end of myofunctional therapy — or the biggest marketing gift you have ever been handed? Because right now, the scuttlebutt is loud. Myofunctional therapists are panicking in Facebook groups, DMs, and inboxes. And the truth is that most of them have this story backwards. The sleep apnea pill is not your competition. It is your billboard. And if you know how to use it, the next twelve months can be the most visible, most credible, and most profitable season you have had yet.

Prefer to Listen Instead?

This article is based on The Profitable Myofunctional Therapist™ podcast, Episode 71: The New Sleep Apnea Pill: What Every Myofunctional Therapist Needs to Know. You can listen to the podcast here.

Prefer to Watch Instead?

What the New Sleep Apnea Pill Actually Does

The Lancet FLOW Trial was published in 2025 and hit the mainstream news cycle in March of 2026. The sleep apnea pill at the center of it is a repurposed epilepsy medication called sulthiame, which reduced breathing interruptions in people with moderate to severe obstructive sleep apnea.

In plain English, here is what the sleep apnea pill does.

Some people with sleep apnea have a breathing control system that is too sensitive. Their brain overreacts to small shifts in carbon dioxide at night. Breathing gets jumpy. The airway muscles relax. The airway collapses. Researchers call this high loop gain — think of it like a thermostat that keeps cranking the heat up and down because it cannot settle.

This sleep apnea pill dampens that thermostat. Breathing smooths out.

And here is the part most therapists miss. The researchers also found the drug improved upper airway muscle tone. Their words. Not mine.

That is your whole job.

Why the Sleep Apnea Pill Is Validation, Not Competition

For years, myofunctional therapists have been the weirdos at the airway table. We have been teaching correct tongue posture. We have been preaching nasal breathing. We have been coaching muscle function.

Now, a major medical journal publishes a drug trial — and what is the drug doing? Stabilizing upper airway function. The same thing we have been doing for years without a prescription.

Pharma did not invent this idea. They are catching up to us.

And here is the stat that should put the pep back in your step. Peer-reviewed research shows myofunctional therapy reduces AHI by approximately 50% in adults and 62% in children. The new drug reduced breathing interruptions by up to 47% at the highest dose.

We have been outperforming this thing for years.

So when you see therapists clutching their pearls over this news, remember what is actually happening. The medical establishment just put your mechanism of action on the front page. This is not your ending. This is your billboard.

Why the Sleep Apnea Pill Expands Your Market Instead of Shrinking It

Here is where most therapists get it completely backwards. They hear “sleep apnea drug,” and they think competition. Dead wrong.

When a story like this drops, something happens that has nothing to do with the drug itself. Millions of people who never thought about sleep apnea suddenly do. They Google it. They ask their dentist. They mention it to their spouse.

That is free awareness (AKA: Free marketing!!) — paid for by pharma’s marketing budget and dropped right into your lap.

Some of those people will try the sleep apnea pill. Fine. Some will not qualify. Some will try it and realize it does not fix their root problem, because their root problem is a tongue living on the floor of their mouth.

And a significant group will want a non-drug option from day one.

Every one of those people is a door cracking open.

But doors only matter if somebody is standing in them. The therapists who panic and retreat this week miss the whole wave. The therapists who show up — post about it, email their list, mention it to their dental colleagues — those are the ones who get clients. Not because they are smarter. Because they are visible.

The therapists who are already losing this moment are the ones who still think the problem is that they are not getting myofunctional therapy clients. The real problem is that nobody sees them. And when pharma’s marketing engine hands you a national news cycle for free, invisibility becomes very expensive.

You Are the Root-Cause Option — Own It

Here is what I want you to never forget.

Pills treat symptoms. CPAP treats symptoms. Oral appliances treat symptoms. All legitimate tools. CPAP saves lives, period.

But none of them — none — address why the airway is collapsing in the first place.

That is your lane.

You are not in the “instead of” business. You are in the “fix what nothing else can” business. The sleep apnea pill does not teach a tongue where to rest. The mask does not retrain a swallow. The appliance does not fix mouth breathing during the day.

Only you do that.

So say this out loud — right now, wherever you are.

“I don’t compete with the pill. I address what the pill can’t.”

That is your positioning sentence. That is your anchor. That is what you say when a prospect asks. That is what you say when a skeptical spouse pushes back.

The 3-Part Framework: When a Client Asks “Can’t I Just Take a Pill?”

This conversation is coming — whether you are ready or not. Here is the exact script.

Step One: Validate the Question

Do not get defensive. Do not sigh. Do not act like they insulted your profession.

Say: “That’s a great question. The research on these new drugs is exciting. We don’t see a lot of successful pharmaceutical options for sleep apnea — and that matters.”

One sentence. Done. You just positioned yourself as informed, current, and unbothered.

Step Two: Reframe the Size of the Conversation

Here is where most therapists fumble. They shrink. Do not shrink.

Say: “What those drugs do is stabilize breathing during sleep. What I do is retrain how your airway functions 24 hours a day — awake, asleep, eating, talking. The pill works for eight hours. My work shows up in every hour of your life.”

You did not attack the pill. You made the conversation bigger. Two different tools. Two different jobs.

Step Three: Offer the Next Step

No overselling. No underselling.

Say: “If you want to know if you’re a good fit for myofunctional therapy, the best next step is a Free Assessment. I can tell you in 45 minutes whether this is the right tool for you — or if you should start with the medication and add therapy later.”

That is it. You validated them. You positioned yourself as a pro who picks the right tool for the right person. You removed the pressure. You gave one clear next step.

Memorize it. Rehearse it in the shower. Put it in your notes app. Because the ready therapists are the ones who convert.

How to Actually Use This News Cycle to Get Clients

The therapists who turn this moment into paying clients will not do anything complicated. They will do three simple things — consistently.

They will show up on email. If you have an email list, write to it this week. Not a clinical explanation — a positioning message. Your audience needs to hear that you are current, you are unbothered, and you have a point of view on this news.

They will post about it on social. One post. Two posts. Ten posts if you feel fired up. Use the positioning sentence. Share the three truths. Film a two-minute video explaining the drug and why your work matters more than ever.

They will talk about it with their dental colleagues. Your dentist referral partners are reading the same headlines your patients are. They want to know what you think. Tell them. Then ask if they want a stack of referral cards refilled.

This is not complicated. It is where myofunctional therapists actually get clients — through consistent, visible, relevant action. The news just gave you the relevance for free.

Frequently Asked Questions

What is the new sleep apnea pill?

The new sleep apnea pill is sulthiame — a repurposed epilepsy medication studied in the 2025 Lancet FLOW Trial. It works by dampening overactive breathing control in people with moderate to severe obstructive sleep apnea, smoothing out breathing patterns at night. The study also found it improved upper airway muscle tone — the same outcome myofunctional therapy has been producing for years.

Will the sleep apnea pill replace myofunctional therapy?

No. The pill treats symptoms during sleep. Myofunctional therapy retrains how the airway functions 24 hours a day — awake, asleep, eating, talking. Peer-reviewed research shows myofunctional therapy reduces AHI by approximately 50% in adults and 62% in children, while the new drug reduced breathing interruptions by up to 47% at the highest dose. The pill is validation of the muscle-tone mechanism, not a replacement for it.

How do I respond when a client asks “can’t I just take a pill?”

Use a three-step framework. First, validate the question: “That’s a great question. The research on these new drugs is exciting.” Second, reframe the conversation: “The pill stabilizes breathing during sleep. My work retrains how your airway functions 24 hours a day.” Third, offer a clear next step: “The best way to know if you’re a good fit for myofunctional therapy is a Comprehensive Exam — I can tell you in 45 minutes whether this is the right tool for you.”

Is myofunctional therapy still relevant with the new sleep apnea drug coming?

Yes — more relevant than ever. The news cycle around the drug is generating massive free awareness about sleep apnea, airway health, and muscle function. Therapists who show up consistently during this moment — on email, on social media, with referral partners — will convert that pharma-funded marketing wave into paying clients. The therapists who panic and retreat miss it entirely.

How effective is myofunctional therapy for sleep apnea compared to the pill?

Peer-reviewed meta-analysis data shows myofunctional therapy reduces AHI by approximately 50% in adults and 62% in children. The new sleep apnea pill reduced breathing interruptions by up to 47% at the highest dose in the Lancet FLOW Trial. Myofunctional therapy has been outperforming this drug’s results for years — without a prescription, without side effects, and with 24-hour functional change instead of overnight symptom management.

Should I be worried about the sleep apnea pill as a myofunctional therapist?

No — but you should be visible. The therapists losing this moment are the ones nobody sees. Pharma’s marketing budget just handed you a national news cycle for free. Use it. Email your list. Post about it. Talk to your dental colleagues. Position yourself as the root-cause option that addresses what the pill can’t. Book a Get Unstuck Call if you need help mapping the strategy.

Ready to Stop Figuring This Out Alone?

If you read this and thought I know what I need to do, but I don’t know how to do it — you’ve got options!

If you’re not trained yet, Learn Myofunctional Therapy in 60 Days is your starting point. Use code T2BCHECKLIST to save $100 on your single payment enrollment.

If you’re trained but only semi-ready to commit to working with a business mentor, then the Trained to Booked Checklist will help you figure out exactly where you are and what your next step is. You can download that now.

If you’re trained and ready to have step-by-step support as you start and grow your myofunctional therapy business, then your next step is to book your Get Unstuck Call! It’s a free 45-minute conversation. We’ll zero in on what’s keeping you stuck and map out your next right move together.

Xo,

💙 Carmen

RESEARCH SOURCES

Lancet FLOW Trial:

• The Lancet publication: https://www.sciencedirect.com/science/article/abs/pii/S0140673625011961
• Apnimed press release: https://apnimed.com/article/apnimed-announces-publication-in-the-lancet-of-positive-phase-2-results-demonstrating-sulthiames-efficacy-in-obstructive-sleep-apnea/
• ScienceDaily coverage: https://www.sciencedaily.com/releases/2026/03/260311004816.htm

Drug Mechanism:

• AJRCCM safety/tolerability: https://www.atsjournals.org/doi/10.1164/rccm.202109-2043OC
• CHEST endotypic traits (muscle tone finding): https://journal.chestnet.org/article/S0012-3692(23)05544-7/fulltext
• PubMed backup: https://pubmed.ncbi.nlm.nih.gov/37776971/
• AJRCCM loop gain editorial: https://www.atsjournals.org/doi/full/10.1164/rccm.202206-1209LE

FDA/Pipeline:

• Tirzepatide/Zepbound OSA: https://theentdr.com/blog/sleep-apnea-medication-latest-update/
• Apnimed AD109 (Science): https://www.science.org/content/article/sleep-apnea-pill-shows-striking-success-large-clinical-trial

Myofunctional Therapy Efficacy:

• Camacho meta-analysis (~50%/62%): https://pmc.ncbi.nlm.nih.gov/articles/PMC4402674/
• Cochrane review: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013449.pub2/full
• 2025 network meta-analysis: https://www.sciencedirect.com/science/article/pii/S1532338225000521
• Kezirian Laryngoscope 2024: https://pubmed.ncbi.nlm.nih.gov/37606313/
• State-of-the-art review: https://pmc.ncbi.nlm.nih.gov/articles/PMC8306407/

About Carmen Ball

Carmen Ball is a myofunctional therapist, business coach, and host of The Profitable Myofunctional Therapist™ podcast. Over the past decade, she has helped thousands of people in her private myofunctional therapy practice (Impact Myofunctional Therapy) and coached hundreds of trained therapists to build profitable online businesses of their own. She is the creator of The Profitable Myofunctional Therapist™ program and Learn Myofunctional Therapy in 60 Days or Less (LMT60), a clinical training program for dental and health professionals. Carmen’s approach is simple: you already have the skills and the license. Now let’s build the business around them. She works with therapists around the world who are ready to stop spinning their wheels and start building a business they are genuinely bonkers about.